Investors Alert: Key Securities Class Action Deadline for Soleno Therapeutics Approaches
In a critical update for investors, Faruqi & Faruqi, LLP is highlighting the impending deadline for a securities class action against Soleno Therapeutics, Inc. As the date approaches, investors who experienced losses while investing in Soleno between March 26, 2025, and November 4, 2025, are advised to reach out to the firm to explore their options.
The concerns about Soleno stem from allegations that the company's Phase 3 clinical trial for its treatment, DCCR, may have obscured serious safety issues related to the drug. Specifically, it is suggested that the risks associated with DCCR, intended for managing hyperphagia in individuals with Prader-Willi syndrome (PWS), were not properly disclosed to investors. The complaint suggests that the company misrepresented facts about its clinical trial program, which potentially concealed significant health risks related to the drug's administration.
A notable report published by Scorpion Capital on August 15, 2025, raised serious doubts about Soleno's clinical data and the efficacy of its drug candidate. Following this publication, Soleno's stock price saw a staggering decline, plummeting by approximately 12% within just two trading days. Furthermore, the company's later disclosures revealed that serious adverse events, including a patient death linked to DCCR, led to further drops in stock value, underlining the urgency of the situation for shareholders.
The deadline to become a lead plaintiff in the lawsuit is set for May 5, 2026, which is an essential date for those looking to recover losses. The lead plaintiff is typically the individual with the largest financial stake in the case who oversees the litigation process on behalf of all affected investors. Anyone interested in pursuing this legal route should consult with experienced attorneys such as those at Faruqi & Faruqi, who have a long history of handling securities litigation and have achieved considerable recoveries for investors since their founding in 1995.
The severity of the allegations against Soleno Therapeutics has raised alarm not just among investors, but also within the Prader-Willi syndrome community. Reports suggest that the company’s reputation has taken a hit, leading to decreased patient engagement and significant drop-offs in treatment initiation rates. As the class action suit gears up, there exists an opportunity for shareholders to come together to seek justice and accountability from the company for the alleged misconduct.
Faruqi & Faruqi encourages anyone with relevant information to reach out, especially whistleblowers, former employees, and current shareholders. These individuals may possess insights crucial to the case, further strengthening the claims against Soleno. This situation serves as a stern reminder that investors must remain vigilant and proactive when facing uncertainties related to their investments and public companies.
To find out more about joining the class action or to discuss individual circumstances regarding potential claims, investors can visit Faruqi & Faruqi’s website or directly contact partner Josh Wilson at specified numbers for a confidential conversation.
Investors are urged not to delay and act before the deadline to ensure they don’t miss the opportunity to take part in this pivotal case against a company that has reportedly failed to uphold its responsibilities to its stakeholders.
The concerns about Soleno stem from allegations that the company's Phase 3 clinical trial for its treatment, DCCR, may have obscured serious safety issues related to the drug. Specifically, it is suggested that the risks associated with DCCR, intended for managing hyperphagia in individuals with Prader-Willi syndrome (PWS), were not properly disclosed to investors. The complaint suggests that the company misrepresented facts about its clinical trial program, which potentially concealed significant health risks related to the drug's administration.
A notable report published by Scorpion Capital on August 15, 2025, raised serious doubts about Soleno's clinical data and the efficacy of its drug candidate. Following this publication, Soleno's stock price saw a staggering decline, plummeting by approximately 12% within just two trading days. Furthermore, the company's later disclosures revealed that serious adverse events, including a patient death linked to DCCR, led to further drops in stock value, underlining the urgency of the situation for shareholders.
The deadline to become a lead plaintiff in the lawsuit is set for May 5, 2026, which is an essential date for those looking to recover losses. The lead plaintiff is typically the individual with the largest financial stake in the case who oversees the litigation process on behalf of all affected investors. Anyone interested in pursuing this legal route should consult with experienced attorneys such as those at Faruqi & Faruqi, who have a long history of handling securities litigation and have achieved considerable recoveries for investors since their founding in 1995.
The severity of the allegations against Soleno Therapeutics has raised alarm not just among investors, but also within the Prader-Willi syndrome community. Reports suggest that the company’s reputation has taken a hit, leading to decreased patient engagement and significant drop-offs in treatment initiation rates. As the class action suit gears up, there exists an opportunity for shareholders to come together to seek justice and accountability from the company for the alleged misconduct.
Faruqi & Faruqi encourages anyone with relevant information to reach out, especially whistleblowers, former employees, and current shareholders. These individuals may possess insights crucial to the case, further strengthening the claims against Soleno. This situation serves as a stern reminder that investors must remain vigilant and proactive when facing uncertainties related to their investments and public companies.
To find out more about joining the class action or to discuss individual circumstances regarding potential claims, investors can visit Faruqi & Faruqi’s website or directly contact partner Josh Wilson at specified numbers for a confidential conversation.
Investors are urged not to delay and act before the deadline to ensure they don’t miss the opportunity to take part in this pivotal case against a company that has reportedly failed to uphold its responsibilities to its stakeholders.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.